About LOERadar
Built where Hatch-Waxman judgment meets structured data.
LOERadar is a Polsinelli-sponsored intelligence platform created by Mark Deming—Polsinelli’s Hatch-Waxman & Biologics Vice Chair, a registered patent attorney, and a computer engineer. He built it for his own practice first. It now serves the work pharmaceutical professionals do every day: turning a scattered public record into timely strategic context.
Built by Mark Deming at Polsinelli.
The problem
A Tool Born from the Work
Drug-competition strategy turns on details that rarely sit in one place. Orange Book listings, exclusivity codes, approval histories, PTAB petitions, district-court dockets, citizen petitions, pricing files, securities disclosures—a record spread across seventeen public sources, each on its own clock, each in its own format. The legal question is usually urgent. The sources were never designed to be read together. LOERadar closes the gap.
The builder
Why He Built It
Mark advises brand, generic, and specialty pharmaceutical companies across the full product lifecycle—candidate evaluation, loss-of-exclusivity projection, notice-letter strategy, pre-litigation planning, Hatch-Waxman litigation, post-settlement enforcement. His practice sits where patent rights, FDA regulation, litigation timing, and business strategy converge. That is where a scattered record costs the most.
The philosophy
Technology in Service of Judgment
Software does not practice law. The promise of legal technology is narrower, and more useful: well-built systems make expert judgment faster, sharper, and easier to apply consistently.
LOERadar reflects that discipline. It reads the public record each business day, flags what changed, connects related events, and renders complex drug landscapes in views built to be scanned, compared, and verified. It is designed for professional trust—transparent sourcing, structured presentation, workflows that keep the professional's judgment at the center.
The firm
Backed by a Life Sciences Platform
LOERadar is supported by Polsinelli's Hatch-Waxman, Biologics/Biosimilars, and Life Sciences practices—a multidisciplinary pharmaceutical team of trial attorneys, FDA and antitrust counsel, and patent attorneys and agents, with backgrounds across the sciences that drive drug-development disputes, from organic chemistry to molecular biophysics. LOERadar is a practitioner-built instrument, shaped by the daily realities of pharmaceutical patent litigation, regulatory counseling, and competitive intelligence.